genomics -online.com





Human CMM CRISPR gRNA + Cas9 in Lenti Particles

Overview	
Quantity:	3 x 300 μL
Gene:	Cutaneous Malignant Melanoma/dysplastic Nevus (CMM)
Species:	Human
Insert:	gRNA + Cas9
Vector:	Lentiviral Vector
Application:	Genome Editing with Engineered Nucleases (GEEN), Protein Expression (PExp)
Product Details	
Purpose:	Set of 3 gRNA against CMM in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA and Cas9 in a single vector)
Vector Backbone:	pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro
Promoter:	U6 Promoter, SFFV Promoter
Selectable Marker:	Puromycin
Bacterial Resistance:	Ampicillin
Expression Type:	Stable, Transient
Sequence:	Sequence available upon placing order
Specificity:	GRNAs are designed for use with Cas9 Nuclease only. Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority of cells, except ES cells or iPS cells.
Sequencing Primer:	U6 Forward Primer: 5'TACGTCCAAGGTCGGGCAGGAAGA3'
Components:	Lentiviral particles with a set of 3 gRNAs (3 x 300 μ L) covering different sequences of CMM

Target Details Cutaneous Malignant Melanoma/dysplastic Nevus (CMM) Gene: Alternative Name: CMM **Application Details** Application Notes: Recommended for quality control: Restriction Enzyme Digest and Sequencing Restrictions: For Research Use only Handling Format: Viral Particles -80 °C Storage: Expiry Date: 12 months

Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, (

Publications

Product cited in:

1991)